Matinas BioPharma Holdings Past Earnings Performance
Past criteria checks 0/6
Matinas BioPharma Holdings's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 38% per year.
Key information
-2.4%
Earnings growth rate
5.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 38.0% |
| Return on equity | -133.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Matinas BioPharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -21 | 9 | -2 |
| 30 Jun 24 | 0 | -23 | 10 | 0 |
| 31 Mar 24 | 0 | -23 | 10 | 0 |
| 31 Dec 23 | 1 | -23 | 10 | 0 |
| 30 Sep 23 | 2 | -21 | 11 | 0 |
| 30 Jun 23 | 3 | -21 | 11 | 0 |
| 31 Mar 23 | 4 | -21 | 11 | 0 |
| 31 Dec 22 | 3 | -21 | 11 | 0 |
| 30 Sep 22 | 2 | -24 | 11 | 0 |
| 30 Jun 22 | 1 | -25 | 10 | 0 |
| 31 Mar 22 | 0 | -24 | 10 | 0 |
| 31 Dec 21 | 0 | -24 | 10 | 0 |
| 30 Sep 21 | 0 | -24 | 11 | 0 |
| 30 Jun 21 | 0 | -22 | 11 | 0 |
| 31 Mar 21 | 0 | -23 | 11 | 0 |
| 31 Dec 20 | 0 | -23 | 10 | 0 |
| 30 Sep 20 | 0 | -22 | 9 | 0 |
| 30 Jun 20 | 0 | -21 | 9 | 0 |
| 31 Mar 20 | 0 | -19 | 8 | 0 |
| 31 Dec 19 | 0 | -18 | 8 | 0 |
| 30 Sep 19 | 0 | -16 | 8 | 0 |
| 30 Jun 19 | 0 | -15 | 8 | 0 |
| 31 Mar 19 | 0 | -15 | 8 | 0 |
| 31 Dec 18 | 0 | -15 | 8 | 0 |
| 30 Sep 18 | 0 | -15 | 8 | 0 |
| 30 Jun 18 | 0 | -15 | 8 | 0 |
| 31 Mar 18 | 0 | -16 | 7 | 0 |
| 31 Dec 17 | 0 | -33 | 8 | 0 |
| 30 Sep 17 | 0 | -31 | 6 | 0 |
| 30 Jun 17 | 0 | -34 | 6 | 0 |
| 31 Mar 17 | 0 | -31 | 5 | 0 |
| 31 Dec 16 | 0 | -12 | 4 | 0 |
| 30 Sep 16 | 0 | -12 | 4 | 0 |
| 30 Jun 16 | 0 | -8 | 5 | 0 |
| 31 Mar 16 | 0 | -9 | 5 | 0 |
| 31 Dec 15 | 0 | -9 | 5 | 0 |
| 30 Sep 15 | 0 | -10 | 5 | 0 |
| 30 Jun 15 | 0 | -11 | 5 | 0 |
| 31 Mar 15 | 0 | -11 | 5 | 0 |
| 31 Dec 14 | 0 | -10 | 5 | 0 |
| 30 Sep 14 | 0 | -9 | 5 | 1 |
| 30 Jun 14 | 0 | -8 | 4 | 1 |
| 31 Mar 14 | 0 | -6 | 3 | 2 |
Quality Earnings: MTNB is currently unprofitable.
Growing Profit Margin: MTNB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MTNB is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MTNB has a negative Return on Equity (-133.92%), as it is currently unprofitable.